venBio Global Strategic Fund II L.P. 4
4 · Akero Therapeutics, Inc. · Filed Feb 12, 2020
Insider Transaction Report
Form 4
venBio Global Strategic Fund II L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-02-10$27.08/sh−7,836$212,168→ 3,225,861 total(indirect: See footnote) - Sale
Common Stock
2020-02-11$27.05/sh−2,184$59,068→ 3,233,677 total(indirect: See footnote) - Sale
Common Stock
2020-02-12$27.14/sh−6$163→ 3,233,671 total(indirect: See footnote)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.18, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F3]These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.